Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. - Wikidata - wikimedia - TriplyDB

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

http://www.wikidata.org/entity/Q35214092

about

Association of Anti-VEGF Injections with Progression of Geographic Atrophy The Treatment Paradigm for the Implantable Miniature Telescope Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review Current perspectives on ranibizumab The complexities underlying age-related macular degeneration: could amyloid beta play an important role?Idiopathic preretinal glia in aging and age-related macular degeneration.Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy.VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosis.Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series.Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration.Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration.Genomic Disruption of VEGF-A Expression in Human Retinal Pigment Epithelial Cells Using CRISPR-Cas9 Endonuclease.The Alzheimer's-related amyloid beta peptide is internalised by R28 neuroretinal cells and disrupts the microtubule associated protein 2 (MAP-2).Beyond VEGF-The Weisenfeld Lecture.Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration.GEOGRAPHIC ATROPHY: Semantic Considerations and Literature Review.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.The role of Aflibercept in the management of age-related macular degeneration.VISUALIZING RETINAL PIGMENT EPITHELIUM PHENOTYPES IN THE TRANSITION TO ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Anti-angiogenic Therapy for Retinal Disease.Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Incidence and risk factors of massive subretinal hemorrhage in retinal angiomatous proliferation.Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration.Evolution of Intravitreal Therapy for Retinal Diseases - From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture.An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.RESIDUAL CHOROIDAL VESSELS IN ATROPHY CAN MASQUERADE AS CHOROIDAL NEOVASCULARIZATION ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY: Introducing a Clinical and Software Approach.In Vivo Study of the Long Term Structural Changes Induced by Macular Argon Laser.Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.TOWARDS A TREATMENT FOR DIABETIC RETINOPATHY: Intravitreal Toxicity and Preclinical Safety Evaluation of Inducible Nitric Oxide Synthase Inhibitors.Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

P2860

Q26741294-2C8D0FF4-18EF-4020-AB1E-766C4961705D Q26749297-4BD253D3-F6B2-430C-970A-6B44D6BB1BDB Q26750459-20826B17-BE31-4FA0-8077-0D66D326D75E Q26774188-BBF26378-5D0F-49A6-A15D-7973DC504063 Q26824335-AC3C6D68-1D33-429A-ACF3-25FD7BDE15DB Q28074640-5B6879B7-9FF5-4B23-8F04-4817C36DA494 Q28082383-1B5DEF6A-BBEE-48A9-B0B0-4002F82B8757 Q33702571-720339D1-70FF-4D04-A6BB-31261994E01B Q35721753-0F017B18-06DD-4DF6-ADEE-31F4B0C9E52A Q36247080-40277C63-0F3B-4A79-91F4-FEF528CF6094 Q36706461-81F5093C-A4DE-4EC4-BB1A-9B2F63F1DFE5 Q36904040-9A6C1568-CF37-4F39-A9DE-5CB7F33A5FFD Q36911004-BF453B60-BFEB-48E5-9E86-5EC12557D0AD Q36914264-96222FB4-FE2A-4AB5-A0A0-ED20BD97C4B9 Q37143095-CDB0D0E3-C338-499D-B40C-426E518BADB5 Q37189500-B84FF8B1-B4EC-49AB-94A9-1D527A04EE98 Q37354230-D2590AB8-A44F-44BD-8E0C-8458BD59A936 Q37461113-FE76A639-7E31-4A00-80B6-6E7AD8A1D32B Q37558259-FFEFEFCE-B77A-4EAD-96DA-CA0C724E69AD Q37635057-9C74DB6A-3F0C-4C3E-A8B6-F18DD737C793 Q37681931-1F6AA637-4D6B-4FBF-A81C-7282D0335C48 Q37727288-06559F45-8770-4353-9F8C-2AE5A41E4E44 Q38388508-0FC29215-B70B-4312-9676-31D9B16D87C6 Q38633532-7B62ACED-BD3A-41AB-8C0F-DF5114DF778A Q38777050-6D069AE0-D633-4459-9B5D-616274F463B1 Q38779268-DE7DDFD2-9B5C-4629-8418-39CFB0146A85 Q38805247-C62297A4-6D02-4681-8ACC-89AA74886A8E Q38975099-6969C70C-4BAA-486E-91C3-39D9A609CDF5 Q41460852-1B466C92-D214-4235-9A6B-8B5BFC0079CE Q41504310-61CF81E5-AC96-4B6C-8459-80219A418EEC Q42375827-AECDF702-B060-41CC-8929-1EBFD399C857 Q47108998-9BCC68FB-2E6D-48C5-B8EC-B90730703EFA Q47729194-67EC57AE-8392-471D-ABE1-44CCB04E6138 Q47779475-3DDF5F72-6084-41B6-ABCD-B8CF7A90976C Q48768631-C76168BD-3CA3-4C2B-90A4-D9C94DE1B62C Q50068644-B2895875-FFC9-4D75-B8FC-65C2ADB68259 Q50128630-267344C8-2F10-4D14-8C68-866BAB2BD2C8 Q51248665-EF6A55D5-2259-4375-8681-29AA6C65C6D5 Q51662239-CE0CCEC0-8153-4EA3-BE76-9A716637D11B Q52646207-1B79F321-1614-4F5E-A6FC-216985F831BE

P2860

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

http://www.wikidata.org/entity/Q35214092

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Growth of geographic atrophy i ...... egeneration treatments trials.

@ast

Growth of geographic atrophy i ...... egeneration treatments trials.

@en

type

label

Growth of geographic atrophy i ...... egeneration treatments trials.

@ast

Growth of geographic atrophy i ...... egeneration treatments trials.

@en

prefLabel

Growth of geographic atrophy i ...... egeneration treatments trials.

@ast

Growth of geographic atrophy i ...... egeneration treatments trials.

@en

P1433

Q35214092-275F5A79-6C4F-4114-A84C-877F450D808D

P1476

Q35214092-BBC9AE72-C000-4B60-9322-F204948297A7

P2093

Q35214092-0383DD3A-BB43-412F-AE5C-0830011A0D48

Q35214092-64D6958D-4F38-4AD5-A967-455A09BA4C39

Q35214092-81EE356B-3C36-479D-B909-5001AAD4494B

Q35214092-95D4BB48-A33F-4518-B52B-29799FA67D3B

Q35214092-9C1914CB-E83F-4F2B-9D42-4FE1AABD4692

Q35214092-A9362164-1053-42CE-B97C-1FB5D92ECA3F

Q35214092-E909F945-5E34-47BB-B48B-A7968D464000

P2860

Q35214092-080C6839-CFFE-45DC-BBFF-FEC171A4E6C7

Q35214092-3180963E-E6B1-4322-92C1-C2464146865F

Q35214092-3573C160-6B65-4CB5-B37C-60C49E8F0804

Q35214092-36D7EC27-571E-487D-B219-F56D2C743B6C

Q35214092-38448A5A-3146-481C-9AA3-31C0E96F15E6

Q35214092-5F7667B3-9B48-4560-B9BE-26A6A51DCECF

Q35214092-66FEC48F-D4EB-4EFA-B984-06843B7CA309

Q35214092-672CE089-345B-4627-B288-1B364A96FDF1

Q35214092-79DCA801-D040-4E13-9EEB-EE87F2868343

Q35214092-811A66C1-B218-41B2-937A-D94DB7BC6213

P304

Q35214092-6B9428A9-59B6-40B1-9F27-66137653157A

P31

Q35214092-5CCF3669-BBAF-4EFC-9D7B-8907FDD04566

P356

Q35214092-F0E879DD-B3DD-4A0D-A521-06D1DFD70D8C

P433

Q35214092-89838B33-D439-41FD-8CCD-AB0A30C0D117

P478

Q35214092-731C7A38-A0EF-4F2C-B356-41BC6B5C9943

P577

Q35214092-35F97386-9097-406C-B38A-B7D7965790E9

P698

Q35214092-47B0AE59-BDEC-4799-A4B2-1F49B3C77A3D

P932

Q35214092-D45ACAAC-99A6-4A73-B1B7-E10285EE63A9

P356

J.OPHTHA.2014.11.007

P1433

P1476

Growth of geographic atrophy i ...... egeneration treatments trials.

@en

P2093

Comparison of Age-related Macular Degeneration Treatments Trials Research Group

http://www.w3.org/2001/XMLSchema#string

Daniel F Martin

http://www.w3.org/2001/XMLSchema#string

Ebenezer Daniel

http://www.w3.org/2001/XMLSchema#string

Gui-Shuang Ying

http://www.w3.org/2001/XMLSchema#string

Juan E Grunwald

http://www.w3.org/2001/XMLSchema#string

Maureen G Maguire

http://www.w3.org/2001/XMLSchema#string

Maxwell Pistilli

http://www.w3.org/2001/XMLSchema#string

P2860

CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Prevalence of age-related macular degeneration in the United States

Ranibizumab for neovascular age-related macular degeneration

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26.

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials

Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.

P304

809-816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2014.11.007

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25542520

http://www.w3.org/2001/XMLSchema#string

P932

4372487

http://www.w3.org/2001/XMLSchema#string